US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Birth Control

2,538.91

-5.4336-0.21%

Number of Gainers:3

Number of Losers:2

Number of Flat:- -

PE:- -

High:2,596.63

Open:2,545.80

Low:2,537.54

Close:2,544.35

Volume:23.58M

Turnover:131.49M

Market Cap:40.83B

Float Cap:40.00B

Loading ...

MannKind Shareholders Reaffirm Board, Pay, and Auditor Roles

MannKind shareholders elect nine directors at annual meeting

Teva announces EMA acceptance of MAA for olanzapine long-acting injectable

BRIEF-Daré Bioscience Initiates Phase 2 Study Of Dare-Hpv

Evofem Biosciences Q1 sales edge up on higher pricing

Evofem reports Q1 EPS (4c) vs. 0c last year

Evofem Reports First Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS

Evofem Biosciences Q1 Income From Operations USD -4.569 Million

THOMSON REUTERS

Daré Bioscience starts Phase 2 trial of DARE-HPV vaginal insert for high-risk HPV infection

Teva Study Finds Only 23% of Younger Adults With Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed With TD Despite Widespread Impact

THOMSON REUTERS

DarÉ Bioscience Initiates Phase 2 Study of Dare-Hpv, a Novel Pharmacologic Treatment for Persistent High-Risk Hpv Infection With No FDA-Approved Therapies

THOMSON REUTERS

Dare Bioscience Inc - Dare-Hpv Development Supported by $10 Mln Arpa-H Contract; Topline Data Expected in 2027

THOMSON REUTERS

Dare Bioscience Inc - Phase 2 Study to Enroll About 100 Women Over up to 21 Days

THOMSON REUTERS

Evofem Biosciences Q1 EPS $(0.04), Sales $899.000K Up From $845.000K YoY

Evofem net loss widens to $5.5 million in Q1 FY26; net product sales rise 6% to $899,000

Veru : Oppenheimer Cuts Target Price to $24 From $25

THOMSON REUTERS

Dare Bioscience Inc reports results for the quarter ended December 31 - Earnings Summary

BRIEF-Daré Bioscience Reports First Quarter 2026 Financial Results

Dare Bioscience Q1 FY26 net loss narrows 31% to $3 million

Dare Bioscience, Inc. Q1 EPS USD -0.2

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4584/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"Birth Control","latestPrice":2538.9136,"timestamp":1779479999999,"preClose":2544.3472,"halted":0,"volume":23580316,"delay":0,"changeRate":-0.002136,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-5.433594,"latestTime":"05-22 16:00:00 EDT","open":2545.7969,"high":2596.6267,"low":2537.5366,"amount":131492535.546006,"amplitude":0.023224,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779802200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.979722,"peRate":27.20251,"turnoverRate":0.015506,"increases":3,"decrements":2,"flats":0,"marketCap":40834947304,"floatMarketCap":39997622874},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":2596.6267,"amplitude":0.023224,"preClose":2544.3472,"low":2537.5366,"pbRate":"4.979722","latestPrice":2538.9136,"volume":23580316,"delay":0,"open":2545.7969,"prevYearClose":2379.9924,"prevWeekClose":2538.9136,"prevMonthClose":2602.58,"prevQuarterClose":2236.9697,"fiveDayClose":2550.0078,"twentyDayClose":2278.3528,"sixtyDayClose":2515.2932,"secType":"PLATE","market":"US","turnoverRate":0.015506,"peRate":27.20251,"marketCap":40834947304,"floatMarketCap":39997622874,"timestamp":1779479999999,"nameCN":"Birth Control"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":3,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2637340572","title":"MannKind Shareholders Reaffirm Board, Pay, and Auditor Roles","url":"https://stock-news.laohu8.com/highlight/detail?id=2637340572","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637340572?lang=en_us&edition=fundamental","pubTime":"2026-05-23 07:35","pubTimestamp":1779492956,"startTime":"0","endTime":"0","summary":"The latest update is out from MannKind ( ($MNKD) ). At MannKind’s 2026 Annual Meeting of Stockholders held on May 20, 2026, shareholders elected al...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mannkind-shareholders-reaffirm-board-pay-and-auditor-roles?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mannkind-shareholders-reaffirm-board-pay-and-auditor-roles?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","MNKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637342936","title":"MannKind shareholders elect nine directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2637342936","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637342936?lang=en_us&edition=fundamental","pubTime":"2026-05-23 05:18","pubTimestamp":1779484719,"startTime":"0","endTime":"0","summary":"MannKind held its annual meeting of stockholders on May 20, 2026.Shareholders backed the board’s slate of nine director nominees, setting terms through the next annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDLftzg5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4139","MNKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637235353","title":"Teva announces EMA acceptance of MAA for olanzapine long-acting injectable","url":"https://stock-news.laohu8.com/highlight/detail?id=2637235353","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637235353?lang=en_us&edition=fundamental","pubTime":"2026-05-22 00:35","pubTimestamp":1779381337,"startTime":"0","endTime":"0","summary":"Teva (TEVA) Pharmaceuticals International announced that the European Medicines Agency has accepted the Marketing Authorization Application for ola...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-ema-acceptance-of-maa-for-olanzapine-long-acting-injectable-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-ema-acceptance-of-maa-for-olanzapine-long-acting-injectable-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4215","BK4585","MAA","BK4566","BK4596","BK4584","LU1983299246.USD","BK4557","BK4559","LU2324357040.USD","EPV","BK4081","EMA","BK4588","TEVA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636766060","title":"BRIEF-Daré Bioscience Initiates Phase 2 Study Of Dare-Hpv","url":"https://stock-news.laohu8.com/highlight/detail?id=2636766060","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636766060?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:07","pubTimestamp":1779109645,"startTime":"0","endTime":"0","summary":"BRIEF-Daré Bioscience Initiates Phase 2 Study Of Dare-HpvMay 18 (Reuters) - Dare Bioscience Inc DARE.O:DAR BIOSCIENCE INITIATES PHASE 2 STUDY OF DARE-HPV, A NOVEL PHARMACOLOGIC TREATMENT FOR PERSISTEN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA4QWLYG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4007","DARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636076617","title":"Evofem Biosciences Q1 sales edge up on higher pricing","url":"https://stock-news.laohu8.com/highlight/detail?id=2636076617","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636076617?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:05","pubTimestamp":1779109555,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Q1 sales edge up on higher pricingOverviewUS women's health pharma Q1 sales rose slightly yr/yr, net loss reversed prior yr profitCompany attributed sales growth to higher pricing a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nL1N41V0IX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","LU0203347892.USD","LU0154245756.USD","LU0154245673.USD","BK4149","BK4533","BK4588","EVFM","LU0203345920.USD","CMI","LU0689626769.HKD","BK4007","LU0124676726.USD","BK4567","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636765960","title":"Evofem reports Q1 EPS (4c) vs. 0c last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2636765960","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636765960?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:01","pubTimestamp":1779109266,"startTime":"0","endTime":"0","summary":"Reports Q1 revenue $0.9M vs. $0.8M last year. “Evofem (EVFM) continues to execute our strategy to increase revenues and to diversify and reduce ris...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evofem-reports-q1-eps-4c-vs-0c-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evofem-reports-q1-eps-4c-vs-0c-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","EVFM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636752400","title":"Evofem Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2636752400","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636752400?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:55","pubTimestamp":1779108900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA9MSWSP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4584","EVFM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636075210","title":"Evofem Biosciences Q1 Income From Operations USD -4.569 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2636075210","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636075210?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:55","pubTimestamp":1779108900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nPLXEFF3C7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVFM","BK4584","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636073875","title":"Daré Bioscience starts Phase 2 trial of DARE-HPV vaginal insert for high-risk HPV infection","url":"https://stock-news.laohu8.com/highlight/detail?id=2636073875","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636073875?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:04","pubTimestamp":1779105898,"startTime":"0","endTime":"0","summary":"Daré Bioscience initiated a Phase 2 trial of DARE-HPV, a vaginal insert designed to treat persistent high-risk HPV infection, an area with no FDA-approved drug therapies.Results have not been presented; a topline readout is expected in 2027.The study will assess whether the treatment can clear the virus and reduce the need for prolonged monitoring that often precedes surgical management of cervical disease.The program is supported by a USD 10 million ARPA-H contract, with USD 9 million received to date, providing non-dilutive funding as the asset moves through mid-stage development.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDLbfgVXJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","SG9999014013.SGD","BK4007","SG9999014039.USD","BK4112","LU0314104364.USD","IE00BN0W2W23.USD","LU2210150020.SGD","BK4588","LU2095319765.USD","BK4585","IE00BN0W2T93.GBP","BK4584","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","DARE","SG9999014005.SGD","IE00B64PRP62.GBP","NDAQ","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636078780","title":"Teva Study Finds Only 23% of Younger Adults With Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed With TD Despite Widespread Impact","url":"https://stock-news.laohu8.com/highlight/detail?id=2636078780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636078780?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:00","pubTimestamp":1779105601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUABDTFCH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4596","BK4584","BK4007","BK4566","BK4585","LU2324357040.USD","TEVA","LU1983299246.USD","BK4559","BK4557","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636499078","title":"DarÉ Bioscience Initiates Phase 2 Study of Dare-Hpv, a Novel Pharmacologic Treatment for Persistent High-Risk Hpv Infection With No FDA-Approved Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2636499078","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636499078?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:00","pubTimestamp":1779105600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA4QWLYG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4584","DARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636078203","title":"Dare Bioscience Inc - Dare-Hpv Development Supported by $10 Mln Arpa-H Contract; Topline Data Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2636078203","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636078203?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:00","pubTimestamp":1779105600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA4QWLYG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DARE","BK4584","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636078202","title":"Dare Bioscience Inc - Phase 2 Study to Enroll About 100 Women Over up to 21 Days","url":"https://stock-news.laohu8.com/highlight/detail?id=2636078202","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636078202?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:00","pubTimestamp":1779105600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA4QWLYG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4584","DARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635469053","title":"Evofem Biosciences Q1 EPS $(0.04), Sales $899.000K Up From $845.000K YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2635469053","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635469053?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:55","pubTimestamp":1778882125,"startTime":"0","endTime":"0","summary":"Evofem Biosciences (OTC:EVFM) reported quarterly losses of $(0.04) per share.  The company reported $899.000 thousand in sales this quarter. This is a 6.39 percent increase over sales of $845.000 thousand the same period","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52619821/evofem-biosciences-q1-eps-0-04-sales-899-000k-up-from-845-000k-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Evofem Biosciences Q1 EPS $(0.04), Sales $899.000K Up From $845.000K YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EVFM","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635205822","title":"Evofem net loss widens to $5.5 million in Q1 FY26; net product sales rise 6% to $899,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2635205822","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635205822?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:10","pubTimestamp":1778879419,"startTime":"0","endTime":"0","summary":"Evofem Biosciences posted net loss of $5.5 million for quarter ended March 31, 2026, swinging from net income of $1 million a year earlier.Net product sales rose 6% to $899,000, reflecting higher WAC for PHEXX and stronger SOLOSEC demand, partly offset by lower PHEXX volume following heavy wholesaler buying in December ahead of a January price increase.Total other expense widened to $897,000 from other income of $629,000, driven by $700,000 of interest expense tied mainly to Adjuvant Note and $200,000 loss on fair-value changes in financial instruments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL2CB84D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EVFM","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635108412","title":"Veru : Oppenheimer Cuts Target Price to $24 From $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2635108412","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635108412?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:23","pubTimestamp":1778847800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nAZN4SWKBK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","BK4183","BK4007","BK4557","VERU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635729692","title":"Dare Bioscience Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635729692","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635729692?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:01","pubTimestamp":1778792478,"startTime":"0","endTime":"0","summary":"Dare Bioscience Inc reports results for the quarter ended December 31 - Earnings SummaryDare Bioscience Inc DARE.OQ reported a quarterly adjusted loss of 2 cents per share for the quarter ended Decemb","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL8N41R2JV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DARE","BK4007","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635725849","title":"BRIEF-Daré Bioscience Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635725849","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635725849?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:16","pubTimestamp":1778789807,"startTime":"0","endTime":"0","summary":"BRIEF-Daré Bioscience Reports First Quarter 2026 Financial ResultsMay 14 (Reuters) - Dare Bioscience Inc DARE.O:DARÉ BIOSCIENCE REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATESource text: ID:nGNX9tkHjRFurther company coverage: DARE.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUABPZYVD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DARE","BK4584","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635310723","title":"Dare Bioscience Q1 FY26 net loss narrows 31% to $3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635310723","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635310723?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:04","pubTimestamp":1778789089,"startTime":"0","endTime":"0","summary":"Daré Bioscience posted a net loss of $3 million in the quarter ended March 31, 2026, narrowing 31% from a year earlier as revenue rose to $152,455 from research and development services and royalties.Operating loss narrowed 35% to $3 million, while research and development expense fell 71% to $660,462; selling, general and administrative costs edged down 3% to $2.25 million.Ovaprene Phase 3 enrollment continued, with a May interim review by the data safety monitoring board recommending the study proceed without modification; the company expects to reach at least 2,500 menstrual cycles of exposure in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL28gD7R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4584","DARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635572808","title":"Dare Bioscience, Inc. Q1 EPS USD -0.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2635572808","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635572808?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:03","pubTimestamp":1778789020,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLX17E23C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","DARE","BK4584"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":53,"code":"91000000","status":"200"}]}}